Physician profile
Cheryl Vickers
NPI 1891214383
$1,575.91
in general payments reported to CMS, 2019-2025
27 companies · $455 in 2025
The $455 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $273 · 2022: $267 · 2023: $165 · 2024: $417 · 2025: $455.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,036.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,036.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $481.06 | 2021-2025 | Xifaxan |
| Novo Nordisk INC | $110.51 | 2021-2023 | Ozempic, Rybelsus |
| Biohaven Pharmaceuticals, INC. | $93.95 | 2021 | |
| Axsome Therapeutics, INC. | $87.10 | 2023-2025 | Auvelity |
| Alkermes, INC. | $85.48 | 2022-2025 | Lybalvi, Aristada, Aristada Initio |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $79.21 | 2022-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $77.01 | 2024-2025 | Fanapt |
| Phathom Pharmaceuticals, INC. | $60.96 | 2024-2025 | Voquezna |
| Otsuka America Pharmaceutical, INC. | $51.21 | 2024-2025 | Rexulti |
| Lilly USA, LLC | $49.46 | 2021-2023 | Mounjaro |
| Abbvie INC. | $38.11 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $35.72 | 2023-2024 | Ingrezza |
| Bayer Healthcare Pharmaceuticals INC. | $29.58 | 2021-2022 | |
| Hologic Sales and Service, LLC | $28.91 | 2021-2022 | |
| Lundbeck LLC | $27.37 | 2025 | Rexulti |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $26.50 | 2025 | Dexcom G6 Transmitter |
| Ironshore Pharmaceuticals INC. | $25.90 | 2022-2023 | Jornay Pm |
| Genentech USA, INC. | $25.88 | 2021 | |
| Amarin Pharma, INC. | $25.38 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $23.49 | 2022 | |
| Collegium Pharmaceutical, INC. | $23.11 | 2025 | Jornay Pm |
| Janssen Pharmaceuticals, INC | $18.53 | 2022 | |
| Glaxosmithkline, LLC. | $16.79 | 2025 | Trelegy Ellipta |
| Exact Sciences Corporation | $15.28 | 2024 | Cologuard Collection Kit |
| Teva Pharmaceuticals USA, INC. | $14.69 | 2024 | Austedo Xr |
| Amgen INC. | $12.60 | 2021 | |
| Gilead Sciences, INC. | $12.12 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cheryl Vickers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.